Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients.
Abdrabou AK, Al Sharif F, El Fakih R, Zahrani HA, Al Yamany R, Saleh M, Alhayli S, Al Somali Z, Alotaibi A, AlShaibani A, Deeba F, Asif M, Ahmed SAOA, Al Fraih F, Shaheen M, Alahmari A, Rasheed W, Chaudhri NA, Al Mohareb F, Aljurf M, Hanbali A.
Abdrabou AK, et al. Among authors: al mohareb f.
Ann Saudi Med. 2024 Mar-Apr;44(2):93-103. doi: 10.5144/0256-4947.2024.93. Epub 2024 Apr 4.
Ann Saudi Med. 2024.
PMID: 38615184
Free PMC article.